SPOTLIGHT -
Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder
SPL026 with supportive therapy sees positive results in patients with major depressive disorder.
NDA Accepted for Nasal Nalmefene for Opioid Overdose
The FDA has accepted the NDA for nasal nalmefene, OPNT003, to treat opioid overdose.
25 Years of Poetry of the Times
Celebrating 25 years of Poetry of the Times with Richard Berlin, MD!
FDA-Approved: Risperidone Extended-Release Injectable Suspension
New approval for schizophrenia and bipolar I disorder.
Mental Health Deserts for American Indians and Alaska Natives
How can you better provide care for American Indians and Alaska Natives?
Trial of ADHD Medication with Fast Onset of Action, Entire Active Day Efficacy Initiated
The first phase 3 clinical trial of CTx-1301 for the treatment of ADHD has begun.
Virtual Reality for Patients With Schizophrenia
VR-based training may help improve social cognition and functioning in patients with schizophrenia.
Cariprazine FDA-Approved as Adjunctive Therapy to Antidepressants
Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.
Dementia in the News
What's the latest in dementia?
Predicting Daytime Sleepiness & Fatigue Post-Stroke
Cognitive and psychiatric symptoms at 3 months post-stroke might predict daytime sleepiness and fatigue at 12 months.
Psychopharmacology Conference Offers New Research, Prescribing Tips
Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!
Air Pollution Affects Depressive Symptoms in Bipolar Disorder
New research indicates worsened air quality leads to increased depressive symptoms in patients with bipolar disorder.
Identifying the Symptom of Worthlessness to Prevent Suicide in Adolescents With ADHD
Screening for the symptom of worthlessness could save your adolescent patient’s life…
Assessing 2022: What’s the Prognosis in Psychiatry?
First TAAR1 Agonist Studied as Adjunctive Therapy for MDD
The first patient in a phase 2/3 study evaluating ulotaront for MDD has been enrolled.
Formic Acid as a Urinary Biomarker for Early-Stage Alzheimer Disease
New research finds that a urine test for formic acid could detect early-stage Alzheimer disease.
Phase 3 Trial of Dexmedetomidine for Bipolar I or II, Schizophrenia Doses First Participants
The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.
Tales From the Clinic: Leading by Case Example
Have you missed the latest episodes of the series Tales From the Clinic: The Art of Psychiatry?
Senators Introduce New Bill to Promote Research and Access to MDMA, Psilocybin
A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.
MDMA-Assisted Therapy for PTSD: Completion of Phase 3 Study
The second of a phase 3 study examining MDMA-AT just completed its final participant visit.
The Road to Over-the-Counter Naloxone: FDA Releases Federal Register Notice
We may be one step closer to nonprescription naloxone.
Optimizing Adult ADHD Treatment: An All-Day Affair
ADHD is an all-day affair, and treating it in an adult population can be difficult.
How to Improve Treatment Adherence by Overcoming Antipsychotic Side Effects
What is the impact of antipsychotic side effects on medication adherence?
A Single Dose of Psilocybin for Treatment-Resistant Depression
A single dose of psilocybin could help patients with treatment-resistant depression, according to a new study.
Psychotic Disorders May Nearly Triple Dementia Risk
Individuals with a psychotic disorder are 2.5 times more likely than those without one to develop dementia.
Treating Depression to Prevent Dementia
According to new research, treating depression in older adults could decrease risk of dementia by 51%.
Scariest in Psychiatry
What scares mental health clinicians? We asked, and these brave individuals replied…
Decriminalizing Mental Health: Partnering With Law Enforcement to Reduce Unwanted Outcomes
How can PMHNP consults with law enforcement reduce involuntary transfers and other unwanted outcomes?
App Intervention May Reduce Insomnia in Health Care Workers
Does the YOI intervention improve mental health workers’ insomnia? Research says yes.
ADHD Drugs Negatively Affect Bone Density
Recent research determined the medications modafinil, atomoxetine, and guanfacine negatively impact bones.
